Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Metastasis02:30

Metastasis

5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adjuvant Approaches in Fully Resected Stage III and IV Cutaneous Melanoma: Where Are We Now?

Cancers·2026
Same author

Adjuvant Therapy for High-Risk Stage II Cutaneous Melanoma: Insights and Future Directions.

Cancers·2026
Same author

Insights on Oligometastatic Non-Small-Cell Lung Cancer.

Cancers·2025
Same author

Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR) Common Mutations: New Strategies.

Cancers·2025
Same author

Matters of the Heart: Cardiotoxicity Related to Target Therapy in Oncogene-Addicted Non-Small Cell Lung Cancer.

International journal of molecular sciences·2025
Same author

Immunotherapy in Oncogene-Addicted NSCLC: Evidence and Therapeutic Approaches.

International journal of molecular sciences·2025
Same journal

Predicting Post-Radiotherapy Lymphocyte Recovery for Individualized Risk Stratification in Locally Advanced Esophageal Squamous Cell Carcinoma.

Current oncology (Toronto, Ont.)·2026
Same journal

From Adjunct to Essential: Integrating Supportive Care into Oncology.

Current oncology (Toronto, Ont.)·2026
Same journal

Next-Generation Sequencing in Differentiated Thyroid Cancer Patients Treated with Lenvatinib: Results and Challenges in Real-Life Practice.

Current oncology (Toronto, Ont.)·2026
Same journal

The Route of Administration Determines the Efficacy of Zinc in Preventing Radiation-Induced Oral Mucositis: A Systematic Review and Meta-Analysis.

Current oncology (Toronto, Ont.)·2026
Same journal

Mechanisms of Progression and Challenges for Intervention in the Natural History of Early Prostate Cancer: A Narrative Review.

Current oncology (Toronto, Ont.)·2026
Same journal

Maintenance Therapy in Acute Myeloid Leukemia: Current Perspectives and Future Directions.

Current oncology (Toronto, Ont.)·2026
See all related articles

Related Experiment Video

Updated: May 26, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1000

Oligometastatic NSCLC: Current Perspectives and Future Challenges.

Sara Torresan1,2, Jacopo Costa1,3, Carol Zanchetta1,3

  • 1Department of Medicine (DME), University of Udine, 33100 Udine, Italy.

Current Oncology (Toronto, Ont.)
|February 25, 2025
PubMed
Summary
This summary is machine-generated.

Oligometastatic non-small cell lung cancer (NSCLC) requires precise definition and multidisciplinary evaluation for optimal patient selection. Tailored locoregional treatments, considering disease timing and type, are crucial for improving survival in this distinct patient group.

Keywords:
NSCLCnon-oncogene-addicted NSCLColigometastaticoligoprogressiveoncogene-addicted NSCLC

More Related Videos

Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay
07:44

Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay

Published on: March 12, 2018

10.0K
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.5K

Related Experiment Videos

Last Updated: May 26, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1000
Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay
07:44

Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay

Published on: March 12, 2018

10.0K
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.5K

Area of Science:

  • Oncology
  • Thoracic Surgery
  • Medical Oncology

Background:

  • Oligometastatic non-small cell lung cancer (NSCLC) presents distinct biology and prognosis compared to widespread stage IV disease.
  • Defining oligometastatic NSCLC and optimizing local treatment strategies remain significant clinical challenges.
  • Current guidelines emphasize shared criteria for patient selection, including comprehensive staging and tissue biopsy.

Purpose of the Study:

  • To review current knowledge, consensus, and trial data on oligometastatic NSCLC.
  • To clarify diagnostic and therapeutic challenges in managing oligometastatic NSCLC.
  • To highlight the need for personalized treatment strategies and identify unmet clinical needs.

Main Methods:

  • Review of international consensus and guidelines.
  • Analysis of retrospective and prospective trial data.
  • Discussion of multidisciplinary evaluation for treatment planning.

Main Results:

  • Multidisciplinary evaluation is crucial for determining amenability to radical local treatment.
  • Distinguishing between de novo oligometastatic disease, oligorecurrence, oligoprogression, and oligoresidual disease is essential for tailored strategies.
  • Immune checkpoint blockers (ICBs) offer new possibilities for consolidative treatments in non-oncogene-addicted NSCLC, though optimal timing and sequencing remain under investigation.

Conclusions:

  • Tailored locoregional approaches are vital for optimizing outcomes in oligometastatic NSCLC.
  • The advent of novel systemic therapies, including ICBs and targeted agents, necessitates re-evaluation of treatment paradigms.
  • Further research is needed to address the unmet clinical needs in the management of oligometastatic NSCLC.